A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

Postmenopausal Osteoporosis Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05060406
• Other study ID #: LY06006/CT-CHN-302
• Status: Recruiting
• Phase: Phase 3
• Start date: June 30, 2019
• Est. completion date: December 31, 2021

Study information

• Verified date: September 2021
• Source: Luye Pharma Group Ltd.
• Contact: Zhenlin Zhang, doctor
• Phone: 13621673716
• Email: zzl2002[@]medmail.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study will be conducted to evaluate the efficacy and safety of LY06006 in the treatment of postmenopausal women with osteoporosis at high risk for fracture, as well as an exploratory population pharmacokinetic analysis of LY06006.

Description:

It is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial.

Primary Objective:

To evaluate the efficacy of LY06006 in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Secondary Objectives:

To evaluate the safety of LY06006. To evaluate the immunogenicity of LY06006. Population pharmacokinetic analysis of LY06006.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 448
• Est. completion date: December 31, 2021
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Postmenopausal woman, ages =50 to =85 years.=3 years postmenopausal, which can be=3 years of spontaneous amenorrhea or =3 years post-surgical bilateral oophorectomy. If < 60 years of age and had hysterectomy but ovarian retention, require follicle stimulating hormone (FSH) levels =40U/L.

Exclusion Criteria:

2. Low BMD (BMD absolute value consistent with a T-score=-2.5 and >-4.0 at either the lumbar spine or total hip). The BMD equivalents by T-score thresholds for each DXA scanner manufacturer are provided below.

3. Have at least one of the following risk factors:

1. history of fragility fracture

2. parental history of hip fracture

3. low body weight (BMI=19kg/m2)

4. elderly (age=65y)

5. current smoker

4. Voluntarily signed written informed consent

Exclusion criteria

1. Bone/metabolic disease:

1. Any metabolic bone disease, e.g., osteomalacia or osteogenesis imperfecta,

2. Paget's disease

3. Cushing's disease

4. Hyperprolactinemia

5. Hypopituitarism

6. Acromegaly

7. Current hyperparathyroidism or hypoparathyroidism by medical record.

8. Current hyperthyroidism or hypothyroidism (allowed if having normal hormone level on thyroid hormone replacement therapy or 5.5µIU/mL<thyroid-stimulating hormone (TSH) level=10.0µIU/mL, but the serum thyroxine (T4) is within the normal range.

9. Malabsorption syndrome or any gastrointestinal disorders associated with malabsorption, for example Crohn's Disease and chronic pancreatitis.

10. Hypocalcemia or hypercalcemia, or serum albumin corrected blood calcium level is not within the normal range of the laboratory;

11. Vitamin D deficiency: 25 hydroxy vitamin D (25OHD) level <20 ng/mL. (allowed 200,000 units of vitamin D2 injection (trade name: Futai®) once during the screening period, and re-test the 25OHD level once. Those with 25OHD level =20 ng/mL can be included

12. Others such as rheumatoid arthritis, gout, multiple myeloma and so on.

2. Subjects with a history of greater than 2 vertebral fractures.

3. Malignancy within the 5 years before enrollment (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ).

4. Severe renal disease, creatinine clearance <30mL/min

5. Liver or biliary diseases:

1. Cirrhosis of the liver;

2. Biliary tract abnormalities (except asymptomatic gallstones);

3. Positive Hepatitis C virus (HCV) antibody;

4. Positive hepatitis B surface antigen (HBsAg) test with the peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) titer test =1×103 copies/mL (if positive HBsAg with the peripheral blood HBV DNA titer test <1× 103 copies/mL, the subject is eligible for selection if the investigator believes that the subject is in a stable phase of chronic hepatitis B and will not increase the risk of the subject,;

5. Alkaline phosphatase <lower limit of normal (LLN); alkaline phosphatase or total bilirubin = 1.5 times the upper limit of normal (ULN); serum aspartate aminotransferase (AST) = 2.0×ULN; serum alanine Acid aminotransferase (ALT) =2.0×ULN;

6. Oral/Dental Diseases

1. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.

2. Active dental or jaw condition which requires oral surgery.

3. Planned invasive dental procedure.

4. Non-healed dental or oral surgery.

7. DXA measurements:

1. Less than two lumbar vertebrae evaluable for DXA measurements.

2. Height, weight, or girth that could preclude accurate DXA measurements.

8. Administration of the following medications:

1. RANKL inhibitor, fluoride or strontium salt or intravenous bisphosphonate within the past 5 years;

2. Oral bisphosphonates, allowed if patients had the following conditions :

• Cumulative use> 3 months but <3 years: = 6 months before the last medication was taken from the screening visit;

• Cumulative use =3 months;

3. parathyroid hormone (PTH) or parathyroid hormone analogs (PTHa) within 6 weeks before screening, such as teriparatide; anabolic hormones or testosterone; glucocorticoids (equivalent to> 5 mg/day strength Pine> 10 days); systemic hormone replacement therapy; selective estrogen receptor modulators (SERMs), such as raloxifene; tibolone; calcitonin; active vitamin D and its analogs; other bone active drugs including anticonvulsants (except benzodiazepines) and heparin; long-term systemic use of ketoconazole, androgens, corticotropin, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, Gonadotropin releasing hormone agonist;

9. Positive human immunodeficiency virus (HIV) antibody.

10. Self-reported alcohol or drug abuse [defined as drinking an average of 14 units or more of alcoholic beverages per week in the 3 months before screening (1 unit = 350 mL of beer, or 45 mL of liquor, or 150 mL of wine)]

11. Known allergy to the treatment drugs used in the research protocol, including allergy to the test drugs

12. Have received any other experimental drug treatment or prior participation in another interventional clinical trial within 3 months before screening

13. Other severe acute or chronic diseases, psychiatric disorder or abnormal laboratory tests, etc., in the opinion of the investigator, not suitable for participating in this research.

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporosis, Postmenopausal
• Postmenopausal Osteoporosis

Intervention

Drug:
• LY06006
60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total

Locations

Country	Name	City	State
China	Shanghai Sixth People's Hospital	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Luye Pharma Group Ltd.	Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine	Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine at Month 12	Baseline and Month 12
Secondary	Percent Change in Bone Mineral Density (BMD) at the Lumbar Spine	Percent Change From Baseline in BMD at the Lumbar Spine at Month 6	Baseline and Month 6
Secondary	Percent Changes in total hip BMD	Percent Changes in total hip BMD from baseline at 6 and 12 months of treatment	Baseline,Month 6 and Month 12
Secondary	Percent Changes in femoral neck BMD	Percent Changes in femoral neck BMD from baseline at 6 and 12 months of treatment	Baseline,Month 6 and Month 12
Secondary	Percent Changes in trochanteric BMD	Percent Changes in trochanteric BMD from baseline at 6 and 12 months of treatment	Baseline,Month 6 and Month 12
Secondary	Percent Change in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline	Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) From Baseline at Month 1, Month 6, and Month 12	Baseline, Month 1, Month 6 and Month 12
Secondary	Percent Change in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline	Percent Change From Baseline in Serum Procollagen Type I N Propeptideserum (s-PINP) From Baseline at Month 1, Month 6, and Month 12	Baseline, Month 1, Month 6 and Month 12